---
title: "Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.25, Implies 31% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292342404.md"
description: "Nurix Therapeutics' 12-month average price target was raised to $32.25 by 16 analysts, up from $31.44, implying a 31% upside based on the July 9 closing price. The consensus rating remains 'Buy', with 15 analysts recommending buys, one holding, and no sells. Price forecasts range from $23 to $45 per share."
datetime: "2026-07-10T16:20:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292342404.md)
  - [en](https://longbridge.com/en/news/292342404.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292342404.md)
generator: "portal-rs"
---

# Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.25, Implies 31% Upside

-   According to estimates from 16 analysts, Nurix Therapeutics, Inc. stock's average price target has risen from $31.44 to $32.25, with forecasts ranging from $23 to $45 per share
-   Based on the Jul. 9 closing price, the updated target implies approximately 31% potential upside
-   Consensus rating remains at “Buy” across 16 covering analysts, with 15 Buys, 1 Holds and 0 Sells

Explore more price target data and ratings for Nurix Therapeutics, Inc. on the , and track all previous and future analyst recommendations for Nurix Therapeutics, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [NRIX.US](https://longbridge.com/en/quote/NRIX.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Attovia Therapeutics, Inc. GAAP EPS of -$4.88 misses by $4.25, revenue of $0.45M](https://longbridge.com/en/news/297827404.md)
- [Mundoro Capital Inc. GAAP EPS of $0.00](https://longbridge.com/en/news/297553342.md)
- [Attovia Therapeutics, Inc. (ATTO) Initiated with a Buy at RBC Capital](https://longbridge.com/en/news/297470988.md)
- [TenX Protocols Inc. reports Q1 results](https://longbridge.com/en/news/297560433.md)
- [Theralase Technologies Inc. reports 1H results](https://longbridge.com/en/news/297369199.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**